Study Summary
A Phase 1 clinical trial to evaluate the safety and early efficacy of Chimeric Antigen Receptor T-cell (CAR T-cell) with IL-7Rα signaling targeting CD19 in children with relapsed and refractory B-cell Acute Lymphoblastic Leukemia (ALL) after complete standard treatments.
Want to learn more about this trial?
Request More InfoInterventions
CD19-IL7Ra CAR-T cellsBIOLOGICAL
Autologous T cells lentiviral transduced to express a CD19-specific chimeric antigen receptor (CAR) with the addition of an IL-7 receptor alpha signaling domain, administered via central venous access catheter after lymphodepletion
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Siriraj Hospital | Bangkok | Bangkoknoi | Thailand |
| Maharaj Nakorn Chiang Mai Hospital | Chiang Mai | Mueang Chiang Mai District | Thailand |
| King Chulalongkorn Memorial Hospital | Bangkok | Pathumwan | Thailand |